PHENOTYPES OF POLYCYSTIC OVARY SYNDROME AND ACCOMPANYING HORMONAL DISTURBANCES

Karatas Savas¹, Hacıoğlu Burcu², Kalaycı Gökhan³

¹Istanbul Research and Education Hospital, Endocrinology and Metabolism Department, 34098 Fatih/İstanbul, Turkey
²Haseki Research and Education Hospital, Internal Medicine Department, 34098 Fatih/İstanbul, Turkey
³Istanbul Research and Education Hospital, Family Medicine Department, 34098 Fatih/İstanbul, Turkey

Primljen/Received 15. 09. 2022.
Prihvaćen/Accepted 05. 10. 2022.

Abstract

**Objective:** PCOS, which is known as a symptom complex including menstrual dysfunction (OD) and or hirsutism/androgen excess (HA), and/or polycystic ovaries (PCOM), induces women's health damage beyond this classical criteria. Subphenotypes of PCOS have different clinical properties and criteria, and the metabolical differences between these phenotypes have not been elucidated properly. Therefore, we aimed to investigate the metabolic and endocrinological differences between these sub-phenotypes.

**Materials and Methods:** 63 patients with PCOS followed by Istanbul Research and Education Hospital Endocrinology and Metabolism Department were included in the study. Patients were classified into subgroups according to phenotypes. The phenotype groups were compared according to blood glucose, lipid parameters, and serum hormone levels. MetS ratios between groups were also compared.

**Results:** Androgen excess/hirsutism was the most prominent character with a 95.2% (n=60) rate in this study group, and ovulatory dysfunction was the least prominent one. (n=43, 68.2%) PCOM has been detected in 50 patients (80.8%). Patients were grouped according to PCOS
Phenotypes. Phenotype C was the most common type, and about 65% of the patients were in this group. Triglyceride levels were statistically significantly higher in the Phenotype A group than in the Phenotype B group (p=0.03). MetS was the highest in the Phenotype A group (45.4%) and the lowest in the Phenotype C group (34.7%).

Conclusions: Phenotype C has the highest prevalence in Turkish patients with PCOS, MetS was the highest in Phenotype A, and TG and LDL cholesterol levels were higher in Phenotype A. More studies are needed to explain these differences and their lifetime consequences.

Keywords: Polycystic ovary syndrome, metabolic syndrome, hyperlipidemia, hirsutism, androgens

INTRODUCTION

Polycystic Ovary Syndrome (PCOS) increasingly attracts more interest as a disease of women of reproductive age. Classically PCOS has been known as a symptoms complex, including menstrual dysfunction (OD) and or hirsutism/androgen excess (HA) and or polycystic ovaries (PCOM). Two of the three latter criteria are sufficient to define diagnosis according to Androgen Excess Society (Rotterdam) criteria (1). Besides these clinical properties, obesity, insulin resistance, and some psychiatric diseases have been attributed to PCOS. According to a meta-analysis of 910 patients, depression and anxiety disorders were more common than in a control group of 1347 subjects (2). According to a Swedish study, 22.4% of the 22385 women with PCOS had previously been diagnosed with at least one psychiatric disorder (2). There are different criteria to define this disorder. According to these criteria, it had been found better to clearly define the PCOS sub-phenotype. These PCOS phenotypes generally include four types: a) phenotype A, clinical or biochemical evidence of HA, OD (menstrual dysfunction), and PCOM; b) phenotype B: HA and OD, but not PCOM; c) phenotype C: HA and PCOM, but not OD; and d) phenotype D, with OD and PCOM, but not HA (3).

Additionally, metabolic syndrome, hyperprolactinemia, and insulin resistance could be other accompanying endocrine disorders in PCOS. One study has found a younger beginning and greater incidence of acne in PCOS patients with hyperprolactinemia (4). However, no study researched PCOS phenotypes and endocrine disturbances, so we aimed to document these endocrine disorders and their relationship with PCOS phenotype.

MATERIAL AND METHODS
63 patients who were routinely followed by Istanbul Research and Education Hospital Endocrinology and Metabolism Department were included in the study. The patients were diagnosed with PCOS according to Androgen Excess Society Criteria (1) and divided into subgroups according to phenotype (3). Height and weight were measured by accustomed methods, and BMI was calculated using the formula weight (in kg) divided by the square of height (in m). Serum lipid parameters, fasting glucose, and insulin were studied after 12 hours of night fasting. Serum estradiol, FSH, LH, testosterone, free testosterone, 17 (OH) Progesterone, and DHEA-S were studied at the follicular phase. Basal cortisol levels were measured at 08 00- 09 00. Overnight 1 mg dexamethasone was administered at 23 00 hrs, and serum cortisol level was measured at 08-09 00 hrs the next morning. The cut-off value for serum cortisol, which was less than 1.8 mcg/dl, was used to exclude hypercortisolism. The phenotype groups were compared according to blood glucose, lipid parameters, and serum hormone levels.

Institutional Ethical approval was taken from Istanbul Research and Education Hospital (27.04.2022/141)/ Helsinki guidelines were applied.

Statistical Analysis

Statistical analysis was performed using SPSS 22.0 (SPSS Inc., Chicago, IL, USA). The Chi-square test or Fischer's test was used to measure the categorical parameters. Student's t-test was used for normal distributed two-group comparisons. A one-way ANOVA test was applied to compare more than two groups. descriptive statistical methods were used to define group characteristics.

RESULTS

63 PCOS patients with a mean age of 24.69±4.76 have been included. Androgen excess/hirsutism was the most prominent characteristic with a 95.2% (n=60) rate in this study group, and ovulatory dysfunction was the least prominent one (n=43, 68.2%). PCOM has been detected in 50 patients (80.8%).

The patients were grouped according to PCOS phenotypes. Phenotype C was the most common type, and about 65% of the patients were in this group. The study population characteristics are shown in Table 1.

There were only two patients with phenotype group D (3.2%). It is not enough to make a statistical comparison with other groups, so phenotype groups A, B, and C were analyzed to compare physical and biochemical properties shown in Table 2. In two group comparisons, triglyceride levels were found to be statistically significantly higher in the phenotype A group
than in the phenotype B group (p=0.03). This relationship was found not significant between groups A and C, and between groups, B and C. LDL levels were also significantly higher in group A compared to group C (p=0.01). When the three groups were compared through an ANOVA test, triglyceride and LDL levels in group A were significantly higher (p =0.04 and p=0.01, respectively).

Table 3 shows the comparison of the hormonal properties of the groups. Although DHEAS levels were statistically higher in group A compared to group B (p=0.03), the three groups' hormonal property comparisons have shown no significant difference between phenotype groups A, B, and C.

**Table 1.** Study population characteristics.

|                          |   |
|--------------------------|---|
| Age                      | 24.69±4.76 |
| Ovulatory Dysfunction    | 43/63 (68.2 %) |
| Androgen Excess/Hirsutism| 60/63 (95.2%) |
| PCO morphology           | 50/63 (80.8%) |
| Phenotype A              | 11/63 (17.4%) |
| Phenotype B              | 9/63 (14.3 %) |
| Phenotype C              | 41/63 (65.1%) |
| Phenotype D              | 2/63 (3.2%) |

**Table 2.** Physical and biochemical properties of the groups.

|                        | A            | B            | P-value Between A and B | C            | P-value Between A and C | P-value Between B and C | p-value     |
|------------------------|--------------|--------------|-------------------------|--------------|-------------------------|-------------------------|------------|
| Weight                 | 77.27±20.08  | 79.00±19.30  | 0.84                    | 73.32±15.47  | 0.48                    | 0.35                    | 0.58       |
| BMI                    | 29.55±6.97   | 31.38±7.47   | 0.63                    | 28.57±6.99   | 0.72                    | 0.35                    | 0.72       |
| Waist                  | 80.80±34.01  | 90.77±22.29  | 0.46                    | 82.28±25.32  | 0.88                    | 0.36                    | 0.33       |
| Glucose                | 86.63±5.98   | 91.75±6.40   | 0.09                    | 92.62±13.11  | 0.14                    | 0.85                    | 0.32       |
| PPG                    | 105.75±21.83 | 79.83±21.70  | 0.07                    | 97.13±22.63  | 0.36                    | 0.09                    | 0.12       |
| Triglyceride           | 154.50±84.95 | 78.50±29.71  | **0.03**                | 100.89±54.10 | 0.06                    | 0.27                    | **0.04**   |
DISCUSSION

This study has demonstrated that PCOS is predominantly found in Phenotype C, and the most common PCOS component is hirsutism and/or androgen excess. On the other side, we couldn’t discover any weight or BMI difference between PCOS phenotypes. Phenotype A, which had included all PCOS criteria, had the highest TG and LDL level and, as expected, had the highest DHEAS level.

Phenotype C (HA+PCOM) was the most common phenotype. This finding was different from previous studies. Panidis et al. found Phenotype A prevalence as 48.2% (5). Another study
found A in 58% prevalence (6). Metabolic syndrome was highest in the Phenotype A group (45.4 %). There have been ethnical differences according to different places and countries. For example, in contrast to the global prevalence of PCOS phenotypes, Phenotype D was found prevalent among Sudanese women (7). Diversity in frequencies of PCOS phenotypes could be clarified by whether the women were investigated in medical care or during an ordinary health control (8).

Serum triglyceride levels as a metabolic syndrome component was significantly the highest in Phenotype A, but also serum LDL cholesterol was highest in Phenotype A. Phenotype A (complete phenotype) had the highest MetS ratio (45.4 %) in the groups, Phenotype C had a similar ratio with Phenotype A (35.7%). Previous studies have found the MetS ratio in PCOS in similar proportions (6,9,10). The most common Mets Criterion was increased waist circumference by 60.3%. However, a recent study from China found low HDL was the most common MetS criterion in patients with PCOS (11). High TG was the most common in the complete phenotype (A). A study from India has found that Phenotype A had the most cardiovascular risk factors, highest waist, and BMI, but also in that study, this phenotype had the highest Clomiphene resistance (12). The difference in our study is there was no difference in weight, body mass index, and insulin levels between the groups, so the effect in blood lipids should not be affected by these parameters. Hyperlipidemia (elevated LDL Cholesterol) was more prominent in Phenotype A. A study from Poland of 93 patients also found higher LDL-cholesterol levels in patients with Phenotype A, while they didn't find a difference in TG levels (12). Total testosterone; FSH and LH and estradiol levels remained similar in phenotype groups. According to a cohort study, the PCOS phenotype didn’t affect oocyte morphology and quality (13).

The importance of PCOS phenotyping lies in the fact that treatment response and cardiovascular prognosis. Adverse pregnancy outcomes were detected as more common in Phenotype A and D after in-vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) (14). Increased risk of abortion after frozen-thawed embryo transfer was found more common in phenotypes A and D (15). According to a cross-sectional study Phenotypes, A and B had weight-related problems in the quality of health, and phenotype D presented more emotional disturbance and relate health quality deterioration (16).

Limitations of this study are its cross-sectional design, small size, and of course, further studies with more molecular investigating and treatment effects could be carried out.
CONCLUSION

Phenotype C has the highest prevalence in Turkish patients with PCOS, MetS was the highest in Phenotype A, and TG and LDL cholesterol levels were higher in phenotype A. More studies are needed to explain these differences and their lifetime consequences.

Abbreviations:

HA- Hyperandrogenism
MetS-Metabolic Syndrome
PCOS-Polycystic Ovary Syndrome

Acknowledgment None.
Conflict of Interests: The authors declare no conflicts of interest related to this article.
Funding: None
Licensing
This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) License

Sažetak

FENOTIPOVI SINDROMA POLICISTIČNIH JAJNIKA I PRATEĆIH HORMONSKIH POREMEĆAJA

Karatas Savas1, Hacıoğlu Burcu2, Kalaycı Gökhan3

1Istanbulska istraživačka i obrazovna bolnica, Odeljenje za endokrinologiju i metabolizam, 34098 Fatih/Istanbul, Turska
2Istraživačka i obrazovna bolnica Haseki, Odeljenje interne medicine 34098 Fatih/Istanbul, Turska
3Istanbulska bolnica za istraživanje i obrazovanje, Odeljenje porodične medicine, 34098 Fatih/Istanbul, Turska

Cilj: PCOS, koji je poznat kao kompleks simptoma koji uključuje menstrualnu disfunkciju (OD) i/ili hirzutizam/višak androgena (HA) i/ili policistične jajnike (PCOM), izaziva oštećenje zdravlja žena izvan ovog klasičnog kriterijuma. Subfenotipovi PCOS-a imaju različita klinička svojstva i kriterijume, a metaboličke razlike između ovih fenotipova nisu pravilno razjašnjene. Stoga smo imali za cilj da istražimo metaboličke i endokrinološke razlike između ovih subfenotipova.
Materijali i metode: U studiju su uključena 63 pacijentkinje sa PCOS-om, praćene na Odeljenju za endokrinologiju i metabolizam Istanbulske istraživačke i obrazovne bolnice. Pacijentkinje su klasifikovane u podgrupe prema fenotipovima. Fenotipske grupe su upoređivane prema glikemiji, lipidnim parametrima i nivou hormona u serumu. MetS odnosi između grupa su takođe upoređivani.

Rezultati: Višak androgena/hirzutizam je bio najistaknutiji karakter sa stopom od 95,2% (n=60) u ovoj studijskoj grupi, a ovulatorna disfunkcija je bila najmanje izražena. (n=43, 68,2%) PCOM je otkriven kod 50 pacijentkinja (80,8%). Pacijentkinje su grupisane prema fenotipovima PCOS. Fenotip C je bio najčešći tip, a oko 65% pacijenatkinja je bilo u ovoj grupi. Nivo triglicerida je bio statistički značajno viši u grupi fenotipa A nego u grupi fenotipa B (p=0,03). MetS je bio najveći u grupi fenotipa A (45,4%), a najmanji u grupi fenotipa C (34,7%).

Zaključak: Fenotip C ima najveću prevalenciju kod turskih pacijenatkinja sa PCOS, MetS je bio najviši kod fenotipa A, a nivoi TG i LDL holesterolâ su bili viši kod fenotipa A. Potrebno je više studija da bi se objasnile ove razlike i njihove posledice tokom života.

Ključne reči: sindrom policističnih jajnika, metabolički sindrom, hiperlipidemija, hirzutizam, androgeni

References

1. Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013;98(12):4565–92. doi: 10.1210/jc.2013-2350.

2. Cesta CE, Månsson M, Palm C, Lichtenstein P, Iliadou AN, Landén M. Polycystic ovary syndrome and psychiatric disorders: Co-morbidity and heritability in a nationwide Swedish cohort. Psychoneuroendocrinology. 2016;73:196–203. doi: 10.1016/j.psyneuen.2016.08.005.

3. Lizneva D, Suturina L, Walker W, Brakta S, Gavrilova-Jordan L, Azziz R. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril. 2016;106(1):6-15. doi:10.1016/j.fertnstert.2016.05.003

4. Wang Y, Hu ZP, Li MZ, Li R, Wang LN, Chen XN, et al. [Effect of hyperprolactinemia upon clinical symptoms of patients with polycystic ovary syndrome]. Zhonghua Yi Xue Za Zhi. 2009;89(37):2599-603. (Article in Chinese).

5. Panidis D, Tziomalos K, Misichronis G, Papadakis E, Betsas G, Katsikis I, et al. Insulin resistance and endocrine characteristics of the different phenotypes of polycystic ovary
syndrome: a prospective study. Hum Reprod. 2012;27(2):541-9. doi:10.1093/humrep/der418

6. Shroff R, Syrop CH, Davis W, Van Voorhis BJ, Dokras A. Risk of metabolic complications in the new PCOS phenotypes based on the Rotterdam criteria. Fertil Steril. 2007;88(5):1389-95. doi:10.1016/j.fertnstert.2007.01.032

7. Elasam AN, Ahmed MA, Ahmed ABA, Sharif ME, Abusham A, Hassan B, et al. The prevalence and phenotypic manifestations of polycystic ovary syndrome (PCOS) among infertile Sudanese women: a cross-sectional study. BMC Womens Health. 2022;22(1):165. doi:10.1186/s12905-022-01762-6

8. Ezeh U, Yildiz BO, Azziz R. Referral bias in defining the phenotype and prevalence of obesity in polycystic ovary syndrome. J Clin Endocrinol Metab. 2013;98(6):1088-96. doi:10.1210/jc.2013-1295.

9. Dokras A, Bochner M, Hollinrake E, Markham S, Vanvoorhis B, Jagasia DH. Screening women with polycystic ovary syndrome for metabolic syndrome. Obstet Gynecol. 2005;106(1):131–7. doi: 10.1097/01.AOG.0000167408.30893.6b.

10. Wild RA, Painter PC, Coulson PB, Carruth KB, Ranney GB. Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1985;61(5):946–5. doi: 10.1210/jcem-61-5-946.

11. Guo F, Gong Z, Fernando T, Zhang L, Zhu X, Shi Y. The lipid profiles in different characteristics of women with PCOS and the interaction between dyslipidemia and metabolic disorder states: a retrospective study in Chinese population. Front Endocrinol (Lausanne). 2022;13:892125. doi:10.3389/fendo.2022.892125

12. Bizoń A, Franik G, Niepsuj J, Czwojdzińska M, Leśniewski M, Nowak A, et al. The associations between sex hormones and lipid profiles in serum of women with different phenotypes of Polycystic Ovary Syndrome. J Clin Med. 2021;10(17):3941. doi:10.3390/jcm10173941

13. Uk A, Decanter C, Grysole C, Keller L, Béhal H, Silva M, et al. Polycystic ovary syndrome phenotype does not have impact on oocyte morphology. Reprod Biol Endocrinol. 2022;20(1):7. doi:10.1186/s12958-021-00874-2

14. Wang Q, Wang H, Li P, Li X, Wang Z, Yan L, et al. Association of polycystic ovary syndrome phenotypes with adverse pregnancy outcomes after in-vitro fertilization/intracytoplasmic sperm injection. Front Endocrinol (Lausanne). 2022;13:889029. doi:10.3389/fendo.2022.889029

15. Wang Q, Zheng Y, Li P, Zhang G, Gao S, Wang Z, et al. Increased risk of abortion after a frozen-thawed embryo transfer in women with polycystic ovary syndrome phenotypes A and D. Sci Rep. 2022;12(1):14852. doi:10.1038/s41598-022-18704-9

16. Li X, Cui T, Song X, Tian W, Lin Y, Zhang H. Comparison of health-related quality of life in different polycystic ovary syndrome phenotypes: A cross-sectional study. Eur J Obstet Gynecol Reprod Biol. 2022;271:189-94. doi:10.1016/j.ejogrb.2022.02.014
Accepted papers are articles in press that have gone through due peer review process and have been accepted for publication by the Editorial Board of Sanamed. The final text of the article may be changed before the final publication. Accepted papers can already be cited using the year of online publication and the DOI, as follows: the author's last name and initial of the first name, article title, journal title, online first publication month and year, and the DOI. When the final article is assigned to volumes/issues of the journal, the Article in Press version will be removed and the final version will appear in the associated published volumes/issues of the journal. The date the article was made available online first will be carried over.

How to cite this article: Karatas S, Hacıoğlu B, Kalaycı G. Phenotypes of polycystic ovary syndrome and accompanying hormonal disturbances. Sanamed. Online First, October 2022. Doi: 10.5937/sanamed0-40164

Correspondence to/Autor za korespondenciju

Karatas Savas
Istanbul Research and Education Hospital, Endocrinology and Metabolism Department
Kasap İlyas Mah, Org. Abdurrahman Nafiz Gürman Cd., 34098 Fatih/Istanbul,Turkey
email: drsavaskaratas@yahoo.com,
phone +90 0212 459 64 99
ORCID:0000-0002-4891-0594